Stay updated with breaking news from Sense diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ The "Global Lab-on-a-Chip Market 2021-2027" report has been added to ResearchAndMarkets.com s offering. The global lab-on-a-chip market is. ....
Credit: Sense Neuro Diagnostics Sense Diagnostics announces initiation of clinical trial to evaluate a non-invasive brain scanner to monitor intracranial hemorrhage SENSE device uses low-power tailored radio frequency (RF) pulse to detect changes that may indicate expanding brain bleed Current standard of care lacks a means to monitor brain injury continuously, non-invasively, in real time, between CT scans CINCINNATI, OH - March 16, 2021 - Sense Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, announced the initiation of a multicenter pivotal trial to evaluate the safety and efficacy of a non-invasive brain scanner to monitor intracranial hemorrhage (ICH) in an acute hospital setting. The SENSE device is a headset equipped with antennae that transmit a low-power tailored radio frequency (RF) pulse across the brain and uses an algorithm to detect signal changes that may indicate an expansion in ICH. ....
Clinical trial begins to evaluate SENSE device’s ability to monitor intracranial hemorrhage Sense Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, announced the initiation of a multicenter pivotal trial to evaluate the safety and efficacy of a non-invasive brain scanner to monitor intracranial hemorrhage (ICH) in an acute hospital setting. The SENSE device is a headset equipped with antennae that transmit a low-power tailored radio frequency (RF) pulse across the brain and uses an algorithm to detect signal changes that may indicate an expansion in ICH. The trial, titled A Prospective, Two-Stage, Non-randomized, Multi-center Within Patient Comparison Study to Evaluate the SENSE Device s Ability to Monitor Intracranial Hemorrhage, follows positive in vitro and in vivo proof of concept studies and a successful first in human feasibility study. The trial will enroll up to 400 patients with a diagnostic head CT s ....